MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology
+$0.05 today
- Market cap
- $80.28M
- Beta
- 0.24
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 2.25M
Average 0.78M
MAIA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
MAIA Biotechnology, Inc.AMEX: MAIA
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $3.53M rose 10.2% year over year, behind the +36.6% change in trailing-twelve-month research & development. Sequentially, it rose 87.3% from the prior quarter. Over 3 fiscal years it compounded at +1076.5% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +10.2% toward the trailing-twelve-month pace of +36.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 14.55B USD
- Year-over-year change
- +145239.2%
- 4-year CAGR
- +705.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.55B | +145239.2% |
| FY2024 | 2024-12-31 | 10.01M | -9.9% |
| FY2023 | 2023-12-31 | 11.11M | +24.4% |
| FY2022 | 2022-12-31 | 8.93M | +158.7% |
| FY2021 | 2021-12-31 | 3.45M | — |
Research & Development vs competitors
How MAIA compares with its peers on the latest reported figures
- MAIA's LTM Mar 2026 research & development of $14.87M is the 4th highest of the 7 companies compared; the peer median is $12.73M.
- Its year-over-year change of +36.6% is the 2nd highest of 7, against a peer median of -11.2%.
- Over three fiscal years its annual growth of +1076.5% compares with a peer median of +2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $16.74B | +90463.6% | +15.1% | — | |
| LTM Mar 2026 | $23.45M | -1.8% | -5.3% | — | |
| LTM Dec 2025 | $15.03M | -13.6% | -42.3% | 56.6% | |
| LTM Mar 2026 | $14.87M | +36.6% | +1076.5% | — | |
| LTM Mar 2026 | $10.43M | -41.5% | -39.6% | — | |
| LTM Mar 2026 | $9.98M | -34.1% | +10.2% | — | |
| LTM Mar 2026 | $5.84M | -8.9% | +13.4% | 392.2% | |
| Peer median (excluding MAIA) | $12.73M | -11.2% | +2.5% | 224.4% | |
Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.45M | 8.93M | 11.11M | 10.01M | 14.55B |
| Selling, General & Admin | 4.29M | 6.14M | 9.07M | 6.95M | 9.72B |
| Operating Expenses | 7.79M | 16.18M | 20.18M | 16.96M | 24.27M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (11.75M) | (15.76M) | (19.77M) | (23.25M) | (22.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.79M) | (16.18M) | (20.18M) | (16.96M) | (24.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.01K | 1.87K | 27.63K | 318.37K | 313.95K |
| Interest Expense | 827.54K | 6.97K | 0 | 57 | 0 |
| Other Income / Expenses | (4.79M) | 406.92K | 409.48K | (6.3M) | 1.87M |
| Income Before Tax | (12.58M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.5M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.18) | (1.70) | (1.49) | (1.05) | (0.70) |
| EPS (Diluted) | (1.18) | (1.70) | (1.49) | (1.05) | (0.70) |
| Weighted Avg Shares | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M |
| Weighted Avg Shares (Diluted) | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M |
MAIA Biotechnology, Inc.
AMEX:MAIA
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.